Bharat Biotech stresses on Covaxin’s safety record after AstraZeneca admits to Covishield causing rare clotting side effects

Following AstraZeneca's acknowledgment in a UK court that its Covid-19 vaccine triggered a rare side effect—Thrombosis with Thrombocytopenia Syndrome (TTS), Hyderabad-based vaccine manufacturer Bharat Biotech emphasized the safety of its indigenous vaccine, Covaxin, aiming to alleviate public apprehensions regarding Covid vaccines. AstraZeneca’s vaccine Vaxzevria, which it developed in collaboration with Oxford University, was manufactured under the Covishield brandname in India.